These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 34476668)

  • 1. Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
    Koufakis T; Papazafiropoulou A; Makrilakis K; Kotsa K
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):315-321. PubMed ID: 34476668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
    Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.
    Wong CKH; Lau KTK; Tang EHM; Lee CH; Lee CYY; Woo YC; Au ICH; Tan KCB; Lui DTW
    Cardiovasc Diabetol; 2022 Jun; 21(1):92. PubMed ID: 35658864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Frederich R; Cherney DZI; Dagogo-Jack S; Pratley RE; Mancuso JP; Maldonado M; Cater NB; Wang S; McGuire DK
    Circulation; 2022 Aug; 146(8):652-654. PubMed ID: 35994565
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Shin H; Schneeweiss S; Glynn RJ; Patorno E
    Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorenal disease management in type 2 diabetes: An expert consensus.
    Mohan V; Singh AK; Zargar AH; Almeida A; Bhalla AK; Mohan JC; Dalal J; Sahay M; Mohanan PP; Maitra S; Ghosh S; Jeloka T; Kaul U; Sakhuja V; Das MK
    Diabetes Metab Syndr; 2022 Dec; 16(12):102661. PubMed ID: 36375366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
    Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
    Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial.
    Bae J; Huh JH; Lee M; Lee YH; Lee BW
    Diabetes Obes Metab; 2021 Feb; 23(2):609-618. PubMed ID: 33217092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.
    Gulsin GS; Graham-Brown MPM; Squire IB; Davies MJ; McCann GP
    Heart; 2022 Jan; 108(1):16-21. PubMed ID: 33972360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes.
    Nazari S; Mirkhani H
    Curr Diabetes Rev; 2023; 19(8):e221222212126. PubMed ID: 36567296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
    Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
    Koufakis T; Mustafa OG; Ajjan RA; Garcia-Moll X; Zebekakis P; Dimitriadis G; Kotsa K
    J Clin Pharm Ther; 2020 Oct; 45(5):883-891. PubMed ID: 31905245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
    Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL
    Diabetes Obes Metab; 2021 Feb; 23(2):382-390. PubMed ID: 33043620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
    Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
    Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.